Kidney Cancer SPORE at Dana-Farber/Harvard Cancer Center
Official title: DF/HCC Kidney Cancer SPORE
Funded at Beth Israel Deaconess Medical Center · NIH-11421794 · Data updated 2026-11-12
A large kidney cancer research program is renewing its funding to translate basic discoveries into new patient treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 18, 2003 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $2,577,865 |
| NIH project number | 2P50CA101942-21A1 |
| Project ID | NIH-11421794 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with kidney cancer who might benefit from new treatments or biomarker-guided approaches could be involved in future translational efforts or trials.
✕Less likely to help
Early-stage or unrelated kidney cancers or those not matching trial criteria may not benefit directly.
What this research studies
This grant supports a long-running, collaborative kidney cancer program based in Boston that brings together several top hospitals and universities. It aims to turn laboratory findings into practical ideas that could help patients with kidney cancer. Researchers work across basic science, biomarker work, and translational studies to speed potential therapies from the lab to the clinic. The program relies on a network of institutions and experienced investigators to tackle biology, treatment strategies, and patient outcomes.
Why it matters
Potential benefit: If successful, the program could lead to new therapies, better biomarkers, and improved care for people with kidney cancer.
How similar studies have gone: Previous SPORE grants in kidney cancer have built strong translational pipelines and collaborative networks, with ongoing progress reported.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Mcdermott, David — Beth Israel Deaconess Medical Center
- Study coordinator: Mcdermott, David
Related research
Other NIH-funded projects on the same topics.
-
Maximizing anti-tumor immune responses in kidney cancer
A cutting-edge program at UT Southwestern aims to speed up better immunotherapy options for kidney cancer by studying how to activate both innate and adaptive immune responses.
-
Kidney Cancer Career Enhancement Program (CEP) at DF/HCC
A career-boosting program supports junior investigators studying kidney cancer to help them advance in basic, translational, and clinical work.
-
Kidney Cancer Development Program at DF/HCC
A funded program at Dana-Farber/Brigham and Women’s Kidney Cancer Center supports new ideas from researchers to improve understanding and treatment of kidney cancer.
-
Personalized antigens for kidney cancer therapy
This grant explores identifying and targeting tumor-specific antigens in kidney cancer to develop more effective, personalized immunotherapies.
-
Optimizing Anti-PD1 Therapy for High-Risk and Metastatic Kidney Cancer
A large cancer research grant is testing how best to use anti-PD-1 therapy to help people with high-risk and metastatic kidney cancer live longer and with fewer side effects.
-
Targeting the HIF2 Pathway in Kidney Cancer
A cancer treatment program aims to see if a drug called belzutifan can help people with a specific kind of kidney cancer whose growth is driven by the HIF2 pathway.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.